Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

59.31USD
19 Jan 2018
Change (% chg)

$0.24 (+0.41%)
Prev Close
$59.07
Open
$59.11
Day's High
$59.67
Day's Low
$58.97
Volume
2,581,804
Avg. Vol
1,694,025
52-wk High
$59.67
52-wk Low
$39.25

Select another date:

Thu, Jan 18 2018

BRIEF-Biogaia signs deal with Abbott to launch probiotic in China

* SAYS HAS SIGNED AN EXCLUSIVE AGREEMENT WITH ABBOTT FOR RIGHTS TO COMMERCIALIZE BIOGAIA PROTECTIS TABS IN CHINA

CMS to cover Abbott's glucose monitoring device

Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States.

CMS to cover Abbott's glucose monitoring device

Jan 4 Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States.

BRIEF-Abbott gets New FDA Labeling For Some Of Its MRI-Ready Devices

* NEW FDA MR-CONDITIONAL LABELING APPROVALS FURTHER EXPAND ABBOTT'S PORTFOLIO OF MRI-READY DEVICES Source text for Eikon: Further company coverage:

BRIEF-Abbott Launches Alinity H-Series Integrated Hematology System

* ABBOTT LAUNCHES ALINITY™ H-SERIES INTEGRATED HEMATOLOGY SYSTEM, COMBINING SPEED, ACCURACY AND SEAMLESS INTEGRATION

BRIEF-Abbott Increases Quarterly Dividend To 28 Cents Per Share

* ABBOTT LABORATORIES - INCREASED COMPANY'S QUARTERLY COMMON DIVIDEND TO 28 CENTS PER SHARE FROM 26.5 CENTS PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan

* Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan Source text for Eikon: Further company coverage:

Fitch Withdraws Abbott Laboratories' Ratings

(The following statement was released by the rating agency) CHICAGO, November 02 (Fitch) Fitch Ratings has chosen to withdraw the ratings of Abbott Laboratories and St. Jude Medical, Inc. for commercial reasons. RATING SENSITIVITIES Ratings sensitivities are no longer relevant given today's withdrawal. FULL LIST OF RATING ACTIONS Fitch has affirmed and subsequently withdrawn the following ratings. Abbott Laboratories --Long-Term Issuer Default Rating 'BBB', Outlook Stable; --Senior unsecured ban

BRIEF-Abbott gets FDA clearance for its Alinity ci-series instruments

* Abbott announces FDA clearance for its Alinity ci-series next-generation diagnostic systems

BRIEF-Abbott says ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​

* Abbott - ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​ Source text for Eikon: Further company coverage:

Select another date: